Trial reportAntimicrobial agents and chemotherapy2019
Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
Trial report in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-ResistantFrontiers in pharmacology · 2022Pooled it
- Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis.Antimicrobial agents and chemotherapy · 2020Pooled it
- Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis.The Journal of clinical investigation · 2020Trial
- Trial
- Antimicrobial Resistance in Major Gram-Positive Pathogens: Beyond the Vancomycin Border.Antibiotics (Basel, Switzerland) · 2026Review
- Methicillin-resistant Staphylococcus aureus.Nature reviews. Disease primers · 2026Review
- An Achilles' heel for methicillin-resistantAntimicrobial agents and chemotherapy · 2026Review
- Impact of early vs delayed initiation of dual antimicrobial salvage therapy on clinical outcomes in MRSA bacteremia.Microbiology spectrum · 2026Observational
- Ceftaroline for Methicillin-Resistant Staphylococcus aureus Endovascular Infection.Infectious diseases and therapy · 2026Review
- Restoration of daptomycin sensitivity with adjunctive cefazolin is associated with C-terminal MprF mutations in MRSA bacteremia isolates.Antimicrobial agents and chemotherapy · 2026Article
- Host-driven remodelling of theMicrobiology (Reading, England) · 2026Review
- ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Pharmacokinetic/Pharmacodynamic Analysis of High-Dose Daptomycin in Combination with Continuous Infusion Ceftobiprole in a Case Series of Documented Staphylococcal Bacteremia or Endocarditis: Is There Any Room for TDM-Guided Dosing Reduction?Antibiotics (Basel, Switzerland) · 2026Article
- Methicillin-resistantAntimicrobial agents and chemotherapy · 2026Article
- Subphenotype- and complication-guided adjunctive fosfomycin versus standard monotherapy inThe Lancet regional health. Europe · 2026Article
- Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Methicillin-resistant and susceptible Staphylococcus aureus: tolerance, immune evasion and treatment.Nature reviews. Microbiology · 2026Review
- Lipopeptide Engineering: From Natural Origins to Rational Design Against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Impact on daptomycin resistance using combination of daptomycin plus ceftaroline in daptomycin-susceptible and -resistantFEMS microbes · 2026Article
- Methicillin-resistantThe Lancet regional health. Western Pacific · 2025Review
56 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
Vancomycin (VAN) and daptomycin (DAP) are approved as a monotherapy for methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.